Is Fezakinumab, an anti-IL22 antibody, a putative novel therapy for a subset of severe asthma? (2019)

First Author: Badi Y

Attributed to: Developing methods for multi-omic data integration and utilisation in pharmaco-genetic and -genomic analysis of drug responders and non-responders funded by BBSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1183/13993003.congress-2019.oa1606

Publication URI: http://dx.doi.org/10.1183/13993003.congress-2019.oa1606

Type: Conference/Paper/Proceeding/Abstract